These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 12192109)
1. Prior increase in metallothionein levels is required to prevent doxorubicin cardiotoxicity. Sun X; Kang YJ Exp Biol Med (Maywood); 2002 Sep; 227(8):652-7. PubMed ID: 12192109 [TBL] [Abstract][Full Text] [Related]
2. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Sun X; Zhou Z; Kang YJ Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. Kang YJ; Chen Y; Yu A; Voss-McCowan M; Epstein PN J Clin Invest; 1997 Sep; 100(6):1501-6. PubMed ID: 9294117 [TBL] [Abstract][Full Text] [Related]
5. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979 [TBL] [Abstract][Full Text] [Related]
6. Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity. Jing L; Wu Y; Wu J; Zhao J; Zuo D; Peng S Eur J Pharmacol; 2011 Jun; 659(2-3):224-32. PubMed ID: 21463615 [TBL] [Abstract][Full Text] [Related]
7. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity. DiSilvestro RA; Liu J; Klaassen CD Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987 [TBL] [Abstract][Full Text] [Related]
8. JAK2/STAT3 Pathway Mediates Protection of Metallothionein Against Doxorubicin-Induced Cytotoxicity in Mouse Cardiomyocytes. Rong J; Li L; Jing L; Fang H; Peng S Int J Toxicol; 2016 May; 35(3):317-26. PubMed ID: 26526549 [TBL] [Abstract][Full Text] [Related]
9. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. Cai L; Wang Y; Zhou G; Chen T; Song Y; Li X; Kang YJ J Am Coll Cardiol; 2006 Oct; 48(8):1688-97. PubMed ID: 17045908 [TBL] [Abstract][Full Text] [Related]
10. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. Zhou G; Li X; Hein DW; Xiang X; Marshall JP; Prabhu SD; Cai L J Am Coll Cardiol; 2008 Aug; 52(8):655-66. PubMed ID: 18702970 [TBL] [Abstract][Full Text] [Related]
11. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496 [TBL] [Abstract][Full Text] [Related]
12. Cardioprotection against doxorubicin by metallothionein Is associated with preservation of mitochondrial biogenesis involving PGC-1α pathway. Guo J; Guo Q; Fang H; Lei L; Zhang T; Zhao J; Peng S Eur J Pharmacol; 2014 Aug; 737():117-24. PubMed ID: 24858368 [TBL] [Abstract][Full Text] [Related]
13. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Mantawy EM; El-Bakly WM; Esmat A; Badr AM; El-Demerdash E Eur J Pharmacol; 2014 Apr; 728():107-18. PubMed ID: 24509133 [TBL] [Abstract][Full Text] [Related]
14. Metallothionein disulfides are present in metallothionein-overexpressing transgenic mouse heart and increase under conditions of oxidative stress. Feng W; Benz FW; Cai J; Pierce WM; Kang YJ J Biol Chem; 2006 Jan; 281(2):681-7. PubMed ID: 16243847 [TBL] [Abstract][Full Text] [Related]
15. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. Wang GW; Klein JB; Kang YJ J Pharmacol Exp Ther; 2001 Aug; 298(2):461-8. PubMed ID: 11454906 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. Wang GW; Kang YJ J Pharmacol Exp Ther; 1999 Mar; 288(3):938-44. PubMed ID: 10027829 [TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration. Saad SY; Najjar TA; Alashari M J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649 [TBL] [Abstract][Full Text] [Related]
18. Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2. Jing L; Yang M; Li Y; Yu Y; Liang B; Cao L; Zhou X; Peng S; Sun Z Food Chem Toxicol; 2017 Dec; 110():204-213. PubMed ID: 29061315 [TBL] [Abstract][Full Text] [Related]
19. Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. Hao E; Mukhopadhyay P; Cao Z; Erdélyi K; Holovac E; Liaudet L; Lee WS; Haskó G; Mechoulam R; Pacher P Mol Med; 2015 Jan; 21(1):38-45. PubMed ID: 25569804 [TBL] [Abstract][Full Text] [Related]
20. Zinc-induced metallothionein overexpression prevents doxorubicin toxicity in cardiomyocytes by regulating the peroxiredoxins. Jing L; Li L; Zhao J; Zhao J; Sun Z; Peng S Xenobiotica; 2016 Aug; 46(8):715-25. PubMed ID: 26599915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]